Genmab Announces Early Results Of Ongoing HuMax-CD4 Trials

... Genmab A/S (CSE: GEN) announced today positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4(R) (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL). In the pivotal CTCL study, clinical response was shown in 5 of 12 patients (42%) in the two highest dose groups. [click link for full article] ...